

Thomas Wanek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2588222/publications.pdf>

Version: 2024-02-01

74
papers

1,844
citations

304743

22
h-index

289244

40
g-index

74
all docs

74
docs citations

74
times ranked

2222
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a ¹⁸ F-labeled Tetrazine with Favorable Pharmacokinetics for Bioorthogonal PET Imaging. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 9655-9659.	13.8	108
2	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with (¹¹ C)-Verapamil and PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1328-1335.	5.0	104
3	Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[¹¹ C]verapamil PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 942-953.	6.4	102
4	Limitations of Small Animal PET Imaging with [¹⁸ F]FDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Imaging and Biology</i> , 2009, 11, 236-240.	2.6	87
5	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. <i>Drug Metabolism and Disposition</i> , 2013, 41, 754-762.	3.3	79
6	Synthesis and in vivo evaluation of [¹¹ C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5489-5497.	3.0	73
7	Design, Synthesis, and Evaluation of a Low-Molecular-Weight ¹¹ C-Labeled Tetrazine for Pretargeted PET Imaging Applying Bioorthogonal in Vivo Click Chemistry. <i>Bioconjugate Chemistry</i> , 2016, 27, 1707-1712.	3.6	73
8	Synthesis and Small-Animal Positron Emission Tomography Evaluation of [¹¹ C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood-Brain Barrier. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6073-6082.	6.4	71
9	(R)-[¹¹ C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. <i>Nuclear Medicine and Biology</i> , 2013, 40, 873-878.	0.6	67
10	Correlated Multimodal Imaging in Life Sciences: Expanding the Biomedical Horizon. <i>Frontiers in Physics</i> , 2020, 8, .	2.1	61
11	A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier. <i>Journal of Neuroscience</i> , 2011, 31, 8803-8811.	3.6	58
12	Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of ¹¹ C-Erlotinib. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1930-1936.	5.0	52
13	A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Blood-Brain Barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 2002-2011.	4.3	46
14	Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 68-77.	1.0	45
15	Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in Pretargeted In Vivo Chemistry. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 824-833.	4.9	45
16	Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2017, 58, 117-122.	5.0	43
17	Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography. <i>Molecular Pharmaceutics</i> , 2015, 12, 3214-3225.	4.6	39
18	Pre vivo, ex vivo and in vivo evaluations of [⁶⁸ Ga]-EDTMP. <i>Nuclear Medicine and Biology</i> , 2007, 34, 391-397.	0.6	37

#	ARTICLE	IF	CITATIONS
19	Gastric Cancer Growth Control by BEZ235 <i>In Vivo</i> Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. <i>Clinical Cancer Research</i> , 2011, 17, 5322-5332.	7.0	33
20	Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2190-2198.	3.0	30
21	EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	24
22	A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 149-159.	6.4	23
23	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. <i>Molecular Pharmacology</i> , 2016, 89, 492-504.	2.3	23
24	Development and performance test of an online blood sampling system for determination of the arterial input function in rats. <i>EJNMMI Physics</i> , 2015, 2, 1.	2.7	22
25	Imaging P-Glycoprotein Induction at the Blood-Brain Barrier of a β 2-Amyloidosis Mouse Model with ¹¹ C-Metoclopramide PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1050-1057.	5.0	21
26	Preclinical in vitro & in vivo evaluation of [11C]SNAP-7941 – the first PET tracer for the melanin concentrating hormone receptor 1. <i>Nuclear Medicine and Biology</i> , 2013, 40, 919-925.	0.6	20
27	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹ C]erlotinib. <i>Molecular Pharmaceutics</i> , 2019, 16, 1282-1293.	4.6	20
28	Reproducibility and Comparability of Preclinical PET Imaging Data: A Multicenter Small-Animal PET Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1483-1491.	5.0	20
29	Age dependency of cerebral P-glycoprotein function in wild-type and APPS1 mice measured with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 150-162.	4.3	20
30	Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 222-226.	2.6	19
31	Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6058-6080.	6.4	18
32	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1219-1225.	0.6	17
33	Effect of Rifampicin on the Distribution of [¹¹ C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. <i>Molecular Pharmaceutics</i> , 2018, 15, 4589-4598.	4.6	17
34	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹ C]erlotinib. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1634-1646.	4.3	17
35	Assessing the Activity of Multidrug Resistance-Associated Protein 1 at the Lung Epithelial Barrier. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1650-1657.	5.0	16
36	Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. <i>Nuclear Medicine and Biology</i> , 2013, 40, 755-763.	0.6	15

#	ARTICLE	IF	CITATIONS
37	Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[¹¹ C]Methylpurine in Mice. <i>Molecular Imaging and Biology</i> , 2019, 21, 306-316.	2.6	15
38	Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [¹¹ C]Tariquidar and PET in Humans and Mice. <i>Molecular Pharmaceutics</i> , 2020, 17, 316-326.	4.6	15
39	Synthesis of a [¹⁸ F]fluorobenzothiazole as potential amyloid imaging agent. <i>Journal of Labelled Compounds and Radiopharmaceutics</i> , 2008, 51, 137-145.	1.0	14
40	On the applicability of [¹⁸ F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. <i>Nuclear Medicine and Biology</i> , 2017, 44, 83-89.	0.6	14
41	Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 954-965.	4.3	14
42	Synthesis and preclinical characterization of 1-(6-deoxy-6-[¹⁸ F]fluoro- β -D)-Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (-allofu assess tumor hypoxia. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5326-5339.	3.0	13
43	[¹⁸ F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 5976-5982.	2.8	13
44	Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [¹¹ C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. <i>Nuclear Medicine and Biology</i> , 2010, 37, 637-644.	0.6	13
45	The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: A positron emission tomography study. <i>Epilepsy Research</i> , 2012, 100, 93-103.	1.6	12
46	Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [¹⁸ F]FBPA in human and mouse tumour cell lines. <i>Applied Radiation and Isotopes</i> , 2016, 118, 67-72.	1.5	12
47	Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [¹¹ C]erlotinib and Positron Emission Tomography. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1093-1100.	3.3	11
48	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. <i>Journal of Controlled Release</i> , 2022, 342, 44-52.	9.9	11
49	Comparison of fully-automated radiosyntheses of [¹¹ C]erlotinib for preclinical and clinical use starting from in target produced [¹¹ C]CO ₂ or [¹¹ C]CH ₄ . <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018, 3, 8.	3.9	10
50	Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. <i>European Journal of Pharmacology</i> , 2012, 696, 18-27.	3.5	9
51	Automated electrophilic radiosynthesis of [¹⁸ F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. <i>Applied Radiation and Isotopes</i> , 2015, 104, 124-127.	1.5	9
52	Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 175.	6.2	8
53	PET imaging of the mouse brain reveals a dynamic regulation of SERT density in a chronic stress model. <i>Translational Psychiatry</i> , 2019, 9, 80.	4.8	7
54	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. <i>Pharmaceutics</i> , 2021, 13, 1286.	4.5	7

#	ARTICLE	IF	CITATIONS
55	Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105854.	4.0	7
56	Cross-Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications. <i>ChemBioChem</i> , 2019, 20, 1530-1535.	2.6	6
57	[¹¹ C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. <i>Nuclear Medicine and Biology</i> , 2017, 52, 7-15.	0.6	6
58	Radiosynthesis of [¹²⁴ I]Iodometomidate and Biological Evaluation Using Small-Animal PET. <i>Molecular Imaging and Biology</i> , 2014, 16, 317-321.	2.6	5
59	[¹⁸ F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 741-749.	6.4	5
60	Automated radiosynthesis of [¹⁸ F]ciprofloxacin. <i>Applied Radiation and Isotopes</i> , 2015, 99, 133-137.	1.5	5
61	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [¹⁸ F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 106-112.	3.3	5
62	Plasma pharmacokinetic and metabolism of [¹⁸ F]THK-5317 are dependent on sex. <i>Nuclear Medicine and Biology</i> , 2020, 84-85, 28-32.	0.6	5
63	Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats. <i>Journal of Controlled Release</i> , 2022, 349, 109-117.	9.9	5
64	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 212-222.	4.0	4
65	Generation and Characterization of an <i>Abcc1</i> Humanized Mouse Model (<i>hABCC1^{flx/flx}</i>) with Knockout Capability. <i>Molecular Pharmacology</i> , 2019, 96, 138-147.	2.3	4
66	Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8245.	4.1	4
67	Evaluation of [¹¹ C]elacridar and [¹¹ C]tariquidar in transporter knockout mice using small-animal PET. <i>NeuroImage</i> , 2010, 52, S25.	4.2	3
68	In vivo characterization of [¹⁸ F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2026-2035.	6.4	3
69	[¹⁸ F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier. <i>Nuclear Medicine and Biology</i> , 2015, 42, 585-589.	0.6	2
70	Humanization of the blood-brain barrier transporter ABCB1 in mice disrupts genomic locus "lessons from three unsuccessful approaches. <i>European Journal of Microbiology and Immunology</i> , 2018, 8, 78-86.	2.8	2
71	Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6514.	4.1	2
72	Small-animal PET evaluation of [¹¹ C]MC113 as a PET tracer for P-glycoprotein. <i>BMC Pharmacology</i> , 2010, 10, .	0.4	0

#	ARTICLE	IF	CITATIONS
73	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	2.5	0
74	Impact of Attenuation Correction on Quantification Accuracy in Preclinical Whole-Body PET Images. Frontiers in Physics, 2020, 8, .	2.1	0